{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0090303",
      "entity_text" : "injury",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:24821094",
      "entity_text" : "ibrutinib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Our patient had normal LFTs before initiation of ibrutinib, negative workup for infectious and autoimmune etiologies of liver injury, and two liver biopsies consistent with drug induced liver injury, leading to the conclusion that ibrutinib was the cause of his liver injury.",
  "reading_complete" : "2020-08-02T08:20:14Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T08:19:43Z",
  "trigger" : "was the cause",
  "evidence" : [ "ibrutinib was the cause of his liver injury" ],
  "pmc_id" : "5458017",
  "score" : 0
}